In the latest trading session, Adma Biologics (ADMA) closed at $16.32, marking a +2.06% move from the previous day. This move outpaced the S&P 500's daily loss of 0.28%. Meanwhile, the Dow lost 0.54%, and the Nasdaq, a tech-heavy index, lost 0.31%.
Shares of the infectious disease drug developer have depreciated by 7.89% over the course of the past month, underperforming the Medical sector's gain of 0.92%, and the S&P 500's loss of 0.76%.
The investment community will be closely monitoring the performance of Adma Biologics in its forthcoming earnings report. The company is scheduled to release its earnings on February 25, 2026.
Looking at the full year, the Zacks Consensus Estimates suggest analysts are expecting earnings of $0.57 per share and revenue of $0 million. These totals would mark changes of +16.33% and 0%, respectively, from last year.
Additionally, investors should keep an eye on any recent revisions to analyst forecasts for Adma Biologics. These latest adjustments often mirror the shifting dynamics of short-term business patterns. Therefore, positive revisions in estimates convey analysts' confidence in the business performance and profit potential.
Our research reveals that these estimate alterations are directly linked with the stock price performance in the near future. To take advantage of this, we've established the Zacks Rank, an exclusive model that considers these estimated changes and delivers an operational rating system.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate remained stagnant. Adma Biologics is currently a Zacks Rank #2 (Buy).
Digging into valuation, Adma Biologics currently has a Forward P/E ratio of 18.81. This valuation marks a discount compared to its industry average Forward P/E of 19.48.
The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry, currently bearing a Zacks Industry Rank of 86, finds itself in the top 36% echelons of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to use Zacks.com to monitor all these stock-influencing metrics, and more, throughout the forthcoming trading sessions.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
ADMA Biologics Inc (ADMA): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
